入选 2025 首都高端领军人才聚集培养工程，斩获香港玻璃体视网膜学会、亚太黄斑视网膜学会两项国际杰出成就讲座大奖。科研成果斩获多项省部级及行业重磅奖项，以第一完成人荣获 2025 年度北京市科学技术奖自然科学二等奖、中国医院协会医院科技创新奖，参与获评湖北省科学技术进步一等奖。
先后主持各级科研基金 14 项，含科技部十四五重大专项、5 项国家自然科学基金及北京市科委重点项目。以第一及通讯作者发表 SCI 论文 40 余篇，多篇刊载于高分国际权威期刊。长期深耕遗传性视网膜病变诊疗领域，主攻眼病基因治疗研发与临床转化，牵头研发的 BCD 基因治疗药物 ZVS101e 顺利进入三期临床试验，先后获评中国突破性疗法、美国 FDA 再生医学先进疗法认定。

累计获批国家发明专利、PCT 专利 10 项，实现千万元成果转化。同时兼任国内多家国家级眼科、遗传、罕见病专业委员会核心职务，在遗传性眼病基础研究、临床诊疗与新药产业化领域造诣深厚，行业影响力突出。

Prof. Liping Yang, Peking University Third Hospital, is a global leader in gene therapy for inherited retinal dystrophies (IRDs). With a Ph.D. from Peking University, she pioneered ZVS101e, the world’s first gene replacement therapy for Bietti crystalline corneoretinal dystrophy (BCD). Launched a clinical trial in 2021, ZVS101e earned US FDA Orphan Drug Designation, China NMPA Breakthrough Therapy status, and US FDA Regenerative Medicine Advanced Therapy certification. Now in Phase III trials, it has shown significant efficacy in more than 60 patients, with related work published in Molecular Therapy, Nature Communications, Progress in Retinal and Eye Research and Signal Transduction and Targeted Therapy. Her team’s RHO gene editing research for retinitis pigmentosa, published in eLife (2023), further showcases her innovation. With over 20 high-impact publications, she has set global standards for IRDs treatment and gene therapy.